Investor Information
Tear Sheet
Latest Financial Reports
8-K - Current report
10-Q - Quarterly report [Sections 13 or 15(d)]
10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Letter to Shareholders
News
15 Sep

03 Aug

Pharmaceutical Technology
BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure
28 Jul

10 Jan

28 Oct

Cardiology Today
Ongoing trial assessing novel assay to determine response to cardiac regenerative therapy
11 May

University of Minnesota
Investigational Therapy Exploring Treatment of Heart Failure Seeks to Stimulate Body’s Natural Healing Response
press releases
Have questions?
CALL US NOW
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
EMAIL US NOW
: info@biocardia.com
biocardia takes a new and comprehensive
approach to heart failure
By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.